BioSpecifics Technologies (BioSpecifics Technologies) Cash-to-Debt : 463.73 (As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioSpecifics Technologies's cash to debt ratio for the quarter that ended in Sep. 2020 was 463.73.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioSpecifics Technologies could pay off its debt using the cash in hand for the quarter that ended in Sep. 2020.

The historical rank and industry rank for BioSpecifics Technologies's Cash-to-Debt or its related term are showing as below:

BSTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: No Debt Max: No Debt
Current: 463.73

During the past 13 years, BioSpecifics Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was No Debt.

BSTC's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.52 vs BSTC: 463.73

BioSpecifics Technologies Cash-to-Debt Historical Data

The historical data trend for BioSpecifics Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioSpecifics Technologies Cash-to-Debt Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

378.13

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	378.13	465.26	480.84	463.73

Competitive Comparison of BioSpecifics Technologies's Cash-to-Debt

For the Biotechnology subindustry, BioSpecifics Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioSpecifics Technologies's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Cash-to-Debt falls into.

BioSpecifics Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioSpecifics Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	89.239	/	(0.069	+	0.167)
	=	378.13

BioSpecifics Technologies's Cash to Debt Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	86.718	/	(0.08	+	0.107)
	=	463.73

BioSpecifics Technologies (NAS:BSTC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioSpecifics Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487